Home

OLPX Q3 Deep Dive: New Product Launches and Brand Investments Offset Market Pressures

OLPX Cover Image

Hair care company Olaplex (NASDAQ:OLPX) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 3.8% year on year to $114.6 million. The company expects the full year’s revenue to be around $420.5 million, close to analysts’ estimates. Its GAAP profit of $0.02 per share was $0.02 above analysts’ consensus estimates.

Is now the time to buy OLPX? Find out in our full research report (it’s free for active Edge members).

Olaplex (OLPX) Q3 CY2025 Highlights:

  • Revenue: $114.6 million vs analyst estimates of $109.9 million (3.8% year-on-year decline, 4.2% beat)
  • EPS (GAAP): $0.02 vs analyst estimates of $0 ($0.02 beat)
  • Adjusted EBITDA: $30.79 million vs analyst estimates of $26.85 million (26.9% margin, 14.7% beat)
  • The company reconfirmed its revenue guidance for the full year of $420.5 million at the midpoint
  • Operating Margin: 3.7%, down from 23.5% in the same quarter last year
  • Market Capitalization: $720.8 million

StockStory’s Take

Olaplex’s third quarter results reflected the early impact of its strategic shift toward coordinated marketing and product innovation. While revenue declined year on year, management credited improvements in sell-through trends to the launch of its new hair masks and a fully integrated 360-degree marketing campaign. CEO Amanda Baldwin noted that these efforts marked “progress in our transformational journey,” and emphasized that the company’s investments in brand health and scientific storytelling are already creating stronger consumer connections. Performance across professional channels was supported by targeted promotions and education, while specialty retail and direct-to-consumer segments continued to experience expected softness.

Looking forward, Olaplex’s guidance is anchored in continued brand investment, targeted international expansion, and a disciplined approach to product innovation. Management highlighted that upcoming product launches, along with the acquisition of Purvala Bioscience, are expected to fuel the company’s R&D pipeline and support long-term growth. CFO Catherine Dunleavy acknowledged ongoing macroeconomic headwinds and an uncertain holiday environment, but reiterated a focus on executing against controllable levers. Baldwin stated, “We are building a platform that balances immediate innovation with bigger, longer-term bets,” signaling that both near-term marketing activations and foundational scientific advances will shape future performance.

Key Insights from Management’s Remarks

Management identified coordinated product launches, brand-building efforts, and improved professional partnerships as key factors influencing the quarter’s results and the company’s outlook.

  • Integrated product launch impact: The debut of Olaplex’s Rich Hydration Mask and Weightless Nourishing Mask was described as the company’s most coordinated launch to date, leveraging a unified marketing and education strategy across all channels, which drove both initial buzz and sustained sales momentum.
  • Brand health improvements: Early results from Olaplex’s brand health tracker showed gains in consumer awareness, consideration, and Net Promoter Score, with the brand now perceived as more approachable while maintaining its scientific identity. Management views these metrics as leading indicators of future demand.
  • Professional channel emphasis: The company’s “Pro-first” approach included targeted blitz events and new educational materials, resulting in above-average sell-through in markets with recent professional engagement. This strategy is intended to reinforce credibility and create a positive feedback loop with stylists.
  • International realignment benefits: Direct investment in select international markets, such as the UK and Japan, led to outperformance versus broader trends, as closer partnerships and enhanced marketing drove stronger results. Partner-led markets are beginning to show early signs of recovery.
  • Innovation pipeline expansion: The acquisition of Purvala Bioscience was highlighted as a foundational step for future product development, with management emphasizing the potential for new technologies and a consistent launch cadence to expand Olaplex’s portfolio within prestige hair care.

Drivers of Future Performance

Management’s outlook centers on balancing ongoing investment in brand and innovation with operational discipline amid market uncertainty.

  • Continued marketing and R&D investment: Olaplex plans to sustain elevated brand-building and innovation spend, leveraging learnings from recent launches to refine its marketing engine and accelerate customer engagement. Management believes these investments are essential for long-term, sustainable growth despite near-term margin pressures.
  • International and professional channel focus: The company expects targeted international investments and professional channel engagement to offset retail headwinds, with early “green shoots” in key regions suggesting that its realigned go-to-market strategy is gaining traction.
  • Macro and holiday headwinds: Management cited an unpredictable macro environment and a promotional holiday season as key risks, especially in direct-to-consumer channels. Plans include adjusting promotional activity as market dynamics unfold and proactively managing inventory to support new launches and minimize destocking pressures.

Catalysts in Upcoming Quarters

In the quarters ahead, our analysts are tracking (1) the performance of Olaplex’s new products and subsequent launches to gauge sustained consumer demand, (2) the ongoing impact of international market investments and realignment on overall sales momentum, and (3) the ability of professional and direct-to-consumer channels to stabilize or grow despite category-wide promotional pressures. Execution on innovation and brand-building initiatives will remain key markers of progress.

Olaplex currently trades at $1.09, up from $1.07 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free for active Edge members).

Our Favorite Stocks Right Now

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.